Switching from etelcalcetide to evocalcet in hemodialysis patients with secondary hyperparathyroidism
Not Applicable
Recruiting
- Conditions
- Secondary hyperparathyroidism
- Registration Number
- JPRN-UMIN000033856
- Lead Sponsor
- Jinken Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Receiving hemodialysis less than three months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with mean intact PTH levels during weeks 20-24 of 60-240 pg/ml.
- Secondary Outcome Measures
Name Time Method Proportion of patients with >=30% reduction from baseline in mean intact PTH levels during weeks 20-24; changes from baseline in serum calcium, phosphorus, intact PTH, and alkaline phosphatase; and adverse events.